![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SHP626 (volixibat), an oral IBAT inhibitor which is being investigated in patients with primary biliary cholangitis and primary sclerosing cholangitis.
Lead Product(s): Volixibat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SHP626
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2024
Details:
SHP626 (Volixibat) is an oral, minimally absorbed agent designed to selectively inhibit IBAT for treatment of adult cholestatic diseases by blocking recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver.
Lead Product(s): Volixibat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SHP626
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
LX9211 achieved the primary endpoint of the study, demonstrating a statistically significant reduction in average daily pain score (ADPS) at week 6 compared to placebo in the low dose arm with results that plateaued in the high dose arm.
Lead Product(s): Volixibat
Therapeutic Area: Neurology Product Name: LX9211
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
The survey results showed that, SHP626 (volixibat) Of the 91% of patients who reported experiencing itch following their diagnosis, 46.4% of respondents experienced >15 episodes (an episode is defined as a prolonged period of itching for at least 7 days).
Lead Product(s): Volixibat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SHP626
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022